

Breathe Easy

with our Pulmonary Package

Streamline your pulmonary drug development process and make faster, better-informed decisions.



Drug Development

- Predict localized drug exposure in the lungs (PBPk/PCAT™)
- Identify applicable pharmacodynamic (PD) endpoints
- Determine the efficacious levels of exposure through quantitative systems pharmacology (QSP)



Expert Insight

- PBPk and QSP experts with 40+ years of combined experience in pulmonary exposure and efficacy modeling
- Active training for your scientists on software tools and models development.



Utilize Software

- Simulation software tailored for use with ILD and IPF predictions
- Integration with GastroPlus® to predict localized exposure in the lungs to inform the ILDsym™ or IPFsym® platforms for efficacy predictions

Ready for your pulmonary program to take off? Let us help.